[1] Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance[J]. Cell, 2008, 133(5): 775-787.
[2] Li B, Greene M I. Special regulatory Tcell review: FOXP3 biochemistry in regulatory T cells—how diverse signals regulate suppression[J]. Immunology, 2008, 123(1): 17-19.
[3] Li B, Samanta A, Song X, et al. FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression[J]. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104(11): 4571-4576.
[4] Li B, Samanta A, Song X, et al. FOXP3 is a homo-oligomer and a component of a supramolecular regulatory complex disabled in the human XLAAD/IPEX autoimmune disease[J]. International Immunology, 2007, 19(7): 825-835.
[5] Chen Z, Barbi J, Bu S, et al. The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3[J]. Immunity, 2013, 39(2): 272-285.
[6] Littman D R, Rudensky A Y. Th17 and regulatory T cells in mediating and restraining inflammation[J]. Cell, 2010, 140(6): 845-858.
[7] Godfrey V L, Wilkinson J E, Russell L B. X-linked lymphoreticular disease in the scurfy (sf) mutant mouse[J]. American Journal of Pathology, 1991, 138(6): 1379-1387.
[8] Bennett C L, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3[J]. Nature Genetics, 2001, 27(1): 20-21.
[9] Wildin R S, Freitas A. IPEX and FOXP3: Clinical and research perspectives[J]. Journal of Autoimmunity, 2005, 25(S): 56-62.
[10] Williams L M, Rudensky A Y. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3[J]. Nature Immunology, 2007, 8(3): 277-284.
[11] Rudra D, Deroos P, Chaudhry A, et al. Transcription factor Foxp3 and its protein partners form a complex regulatory network[J]. Nature Immunology, 2012, 13(10): 1010-1019.
[12] Xiao Y, Li B, Zhou Z, et al. Histone acetyltransferase mediated regulation of FOXP3 acetylation and Treg function[J]. Current Opinion in Immunology, 2010, 22(5): 583-591.
[13] Chae W J, Henegariu O, Lee S K, et al. The mutant leucine-zipper domain impairs both dimerization and suppressive function of Foxp3 in T cells[J]. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103(25): 9631-9636.
[14] Song X, Li B, Xiao Y, et al. Structural and biological features of FOXP3 dimerization relevant to regulatory T cell function[J]. Cell Reports, 2012, 1(6): 665-675.
[15] Ichiyama K, Yoshida H, Wakabayashi Y, et al. Foxp3 inhibits ROR gammatmediated IL17A mRNA transcription through direct interaction with ROR gammat[J]. Journal of Biological Chemistry, 2008, 283(25): 17003-17008.
[16] Du J, Huang C, Zhou B, et al. Isoform-specific inhibition of ROR alphamediated transcriptional activation by human FOXP3[J]. Journal of Immunology, 2008, 180(7): 4785-4792.
[17] Zheng Y, Chaudhry A, Kas A, et al. Regulatory Tcell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses[J]. Nature, 2009, 458(7236): 351-356.
[18] Koch M A, Tucker-Heard G, Perdue N R, et al. The transcription factor Tbet controls regulatory T cell homeostasis and function during type 1 inflammation[J]. Nature Immunology, 2009, 10(6): 595602.
[19] Chaudhry A, Rudra D, Treuting P, et al. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner[J]. Science, 2009, 326 (5955): 986-991.
[20] Pan F, Yu H, Dang E V, et al. Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells[J]. Science, 2009, 325(5944): 11421146.
[21] Rooney J W, Sun Y L, Glimcher L H, et al. Novel NFAT sites that mediate activation of the interleukin-2 promoter in response to T-cell receptor stimulation[J]. Molecular and Cellular Biology, 1995, 15(11): 6299-6310.
[22] Macian F, LopezRodriguez C, Rao A. Partners in transcription: NFAT and AP-1[J]. Oncogene, 2001, 20(19): 2476-2489.
[23] Rao A, Luo C, Hogan P G. Transcription factors of the NFAT family: regulation and function[J]. Annual Review of Immunology, 1997, 15: 707-747.
[24] Wu Y, Borde M, Heissmeyer V, et al. FOXP3 controls regulatory T cell function through cooperation with NFAT[J]. Cell, 2006, 126(2): 375-387.
[25] Zeng W P, Sollars V E, Belalcazar Adel P. Domain requirements for the diverse immune regulatory functions of Foxp3[J]. Molecular Immunology, 2011, 48(15-16): 1932-1939.
[26] Lee S M, Gao B, Fang D. FoxP3 maintains Treg unresponsiveness by selectively inhibiting the promoter DNA-binding activity of AP-1[J]. Blood, 2008, 111(7): 3599-3606.
[27] Haiqi H, Yong Z, Yi L. Transcriptional regulation of Foxp3 in regulatory T cells[J]. Immunobiology, 2011, 216(6): 678-685.
[28] Klunker S, Chong M M, Mantel P Y, et al. Transcription factors RUNX1 and RUNX3 in the induction and suppressive function of Foxp3 + inducible regulatory T cells[J]. Journal of Experimental Medicine, 2009, 206(12): 2701-2715.
[29] Xu L, Kitani A, Stuelten C, et al. Positive and negative transcriptional regulation of the Foxp3 gene is mediated by access and binding of the Smad3 protein to enhancer I[J]. Immunity, 2010, 33(3): 313-325.
[30] Mantel P Y, Kuipers H, Boyman O, et al. GATA3driven Th2 responses inhibit TGFbeta1induced FOXP3 expression and the formation of regulatory T cells[J]. PLoS Biology, 2007, 5(12): e329.
[31] Wang Y, Su M A, Wan Y Y. An essential role of the transcription factor GATA3 for the function of regulatory T cells[J]. Immunity, 2011, 35(3): 337-348.
[32] Samstein R M, Arvey A, Josefowicz S Z, et al. Foxp3 exploits a preexistent enhancer landscape for regulatory T cell lineage specification[J]. Cell, 2012, 151(1): 153-166.
[33] Van Loosdregt J, Vercoulen Y, Guichelaar T, et al. Regulation of Treg functionality by acetylationmediated Foxp3 protein stabilization[J]. Blood, 2010, 115(5): 965-974.
[34] Van Loosdregt J, Fleskens V, Fu J, et al. Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Tregcellsuppressive capacity[J]. Immunity, 2013, 39(2): 259-271.
[35] Shi L Z, Wang R, Huang G, et al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells[J]. Journal of Experimental Medicine, 2011, 208 (7): 1367-1376.
[36] Dang E V, Barbi J, Yang H Y, et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1[J]. Cell, 2011, 146(5): 772-784.
[37] Brunkow M E, Jeffery E W, Hjerrild K A, et al. Disruption of a new forkhead/wingedhelix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse[J]. Nature Genetics, 2001, 27(1): 68-73.
[38] Rudensky A Y, Campbell D J. In vivo sites and cellular mechanisms of T reg cell-mediated suppression[J]. Journal Experimental Medicine, 2006, 203(3): 489-492.
[39] Lehtimaki S, Lahesmaa R. Regulatory T cells control immune responses through their nonredundant tissue specific features[J]. Frontiers in Immunology, 2013, 4: 294.
[40] Belkaid Y, Tarbell K. Regulatory T cells in the control of hostmicroorganism interactions (*) [J]. Annual Review of Immunology, 2009, 27: 551-589.
[41] Han D, Walsh M C, Cejas P J, et al. Dendritic cell expression of the signaling molecule TRAF6 is critical for gut microbiotadependent immune tolerance[J]. Immunity, 2013, 38(6): 1211-1222.
[42] Mason D, Powrie F. Control of immune pathology by regulatory T cells[J]. Current Opinion in Immunology, 1998, 10(6): 649-655.
[43] Powrie F, Leach M W, Mauze S, et al. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice[J]. International Immunology, 1993, 5(11): 14611471.
[44] Aida K, Miyakawa R, Suzuki K, et al. Suppression of Tregs by antiglucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferonalpha gene therapy for pancreatic cancer[J]. Cancer Science, 2013.
[45] Darce J, Rudra D, Li L, et al. An N-terminal mutation of the Foxp3 transcription factor alleviates arthritis but exacerbates diabetes[J]. Immunity, 2012, 36(5): 731-741.
[46] Bettini M L, Pan F, Bettini M, et al. Loss of epigenetic modification driven by the Foxp3 transcription factor leads to regulatory T cell insufficiency[J]. Immunity, 2012, 36(5): 717-730.
[47] Pandiyan P, Zheng L, Ishihara S, et al. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivationmediated apoptosis of effector CD4+ T cells[J]. Nature Immunology, 2007, 8(12): 1353-1362.
[48] Wu H, Li P, Shao N, et al. Aberrant expression of Treg-associated cytokine IL35 along with IL10 and TGFbeta in acute myeloid leukemia[J]. Oncology Letter, 2012, 3(5): 1119-1123.
[49] Collison L W, Workman C J, Kuo T T, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function[J]. Nature, 2007, 450 (7169): 566-569.
[50] Garin M I, Chu C C, Golshayan D, et al. Galectin-1: A key effector of regulation mediated by CD4+ CD25+ T cells[J]. Blood, 2007, 109(5): 2058-2065.
[51] Onishi Y, Fehervari Z, Yamaguchi T, et al. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation[J]. Proceedings of National Academy of Sciences of the United States of America, 2008, 105(29): 1011310118.
[52] Shevach E M. Mechanisms of Foxp3+ T regulatory cell-mediated suppression[J]. Immunity, 2009, 30(5): 636-645.
[53] Delgoffe G M, Woo S R, Turnis M E, et al. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis[J]. Nature, 2013, 501(7466): 252-256.
[54] Gershon R K, Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes[J]. Immunology, 1970, 18(5): 723-737.
[55] Gambineri E, Torgerson T R, Ochs H D. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of Tcell homeostasis[J]. Current Opinion in Rheumatology, 2003, 15(4): 430-435.
[56] Wildin R S, Smyk-Pearson S, Filipovich A H. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome[J]. Journal of Medical Genetics, 2002, 39 (8): 537-545.
[57] Gambineri E, Perroni L, Passerini L, et al. Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, Xlinked syndrome: inconsistent correlation between forkhead box protein 3 expression and disease severity[J]. Journal of Allergy and Clinical Immunology, 2008, 122 (6): 1105-1112 e1101.
[58] Lampasona V, Passerini L, Barzaghi F, et al. Autoantibodies to harmonin and villin are diagnostic markers in children with IPEX syndrome[J]. PLoS One, 2013, 8(11): e78664.
[59] Dunn G P, Old L J, Schreiber R D. The immunobiology of cancer immunosurveillance and immunoediting[J]. Immunity, 2004, 21(2): 137-148.
[60] Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance[J]. Nature Reviews Cancer, 2005, 5(4): 263-274.
[61] Zou W. Regulatory T cells, tumour immunity and immunotherapy[J]. Nature Reviews Immunology, 2006, 6(4): 295-307.
[62] Curiel T J, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival[J]. Nature Medicine, 2004, 10(9): 942-949.
[63] Govindaraj C, Tan P, Walker P, et al. Reducing TNF Receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor panobinostat for clinical benefit in acute myeloid leukemia patients[J]. Clinical Cancer Reserch, 2013.
[64] Martin-Orozco N, Li Y, Wang Y, et al. Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells[J]. Cancer Reserch, 2010, 70(23): 9581-9590.
[65] Sim G C, MartinOrozco N, Jin L, et al. IL2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients[J]. Journal of Clinical Investigation, 2013.
[66] Sugimoto K, Ikeda F, Stadanlick J, et al. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection[J]. Hepatology, 2003, 38(6): 1437-1448.
[67] Park S H, Veerapu N S, Shin E C, et al. Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection[J]. Nature Medicine, 2013, 19(12): 1638-1642.
[68] Kinter A L, Hennessey M, Bell A, et al. CD25(+)CD4(+) regulatory T cells from the peripheral blood of asymptomatic HIVinfected individuals regulate CD4(+) and CD8(+) HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status[J]. Journal of Experimental Medicine, 2004, 200(3): 331-343.
[69] Singh A, Vajpayee M, Ali S A, et al. Cellular interplay among Th17, Th1, and Treg cells in HIV1 subtype "C" infection[J]. Journal of Medical Virology, 2013.
